15/10/2026
A new IOF position statement assesses the potential link between MGUS and fracture risk and offers the first clinical guidance on bone health for patients with MGUS.
📄 Read the full paper (Open Access) here: https://bit.ly/4jKNlAv
Monoclonal gammopathy of undetermined significance (MGUS) is a haematological condition among older adults, yet its impact on bone health is not widely recognised.
IOF hopes the Bone Cancer Working Group's new position statement will raise awareness of this challenging condition and encourage timely recognition and appropriate management of bone fragility in patients with MGUS, such as screening for MGUS when investigating a fragility fracture, undertaking a comprehensive bone evaluation when clinical MGUS is diagnosed, and treating patients at risk with antiresorptive agents at osteoporosis rather than oncology doses.
The paper will be especially relevant to GPs, endocrinologists, rheumatologists, haematologists, gynaecologists, geriatricians, advanced practice nurses, and internists.
Paper Title: “Clinical guidance on evaluation and management of bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS): an IOF position statement
Authors: Cyrille B. Confavreux, Beatrice Bouvard, Robert Blank, Peyman Hadji, Emmanuel Biver, Jean-Jacques Body, Maria Luisa Brandi, Claudia Campusano, Peter R. Ebeling, Abdellah El Maghraoui, Gerold Holzer, David Kendler, Tobie de Villiers, René Rizzoli & A. Joseph Foldes
